Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1486 to 1500 of 7707 results

  1. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)

    Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.

  2. Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)

    Evidence-based recommendations on abiraterone (Zytiga) for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.

  3. HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) (TA92)

    Evidence-based recommendations on using an ozone-releasing device (HealOzone) in people with tooth decay.

  4. Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)

    Evidence-based recommendations on paclitaxel for treating ovarian cancer in adults.

  5. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

    Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.

  6. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

    Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.

  7. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.

  8. Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.

  9. Tacrolimus and pimecrolimus for atopic eczema (TA82)

    Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.

  10. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77)

    Evidence-based recommendations on zolpidem and zopiclone for treating insomnia in adults.

  11. Frequency of application of topical corticosteroids for atopic eczema (TA81)

    Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.

  12. Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

    Evidence-based recommendations on using thrombolytic drugs (alteplase [Actilyse], reteplase [Rapilysin], streptokinase [Streptase] and tenecteplase [Metalyse]) for treating acute myocardial infarction in adults.

  13. Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding (TA78)

    Evidence-based recommendations on fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding in adults.

  14. Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

    Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital.

  15. Laparoscopic surgery for inguinal hernia repair (TA83)

    Evidence-based recommendations on laparoscopic surgery for treating inguinal hernia.